271 related articles for article (PubMed ID: 7459899)
1. High-dose cyclophosphamide versus cyclophosphamide, methotrexate, 5-FU, and hydroxyurea (CMFH) in the treatment of stage III non-small cell bronchogenic carcinoma: a randomized trial.
Pannuti F; Lelli G; Casadio M; Piana E; Di Marco AR
Cancer Treat Rep; 1980; 64(10-11):1131-4. PubMed ID: 7459899
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy for inoperable, non-small cell bronchogenic carcinoma: EST 2575, generation II.
Ruckdeschel JC; Mehta CR; Salazar OM; Cohen M; Vogl S; Koons LS; Lerner H
Cancer Treat Rep; 1981; 65(11-12):965-72. PubMed ID: 7028258
[TBL] [Abstract][Full Text] [Related]
3. [Cytostatic therapy of tumors of the lung].
De Marco F; Saviano G; Tenore G
Arch Monaldi; 1974; 29(3-4):326-35. PubMed ID: 4463917
[No Abstract] [Full Text] [Related]
4. Chemotherapy in bronchogenic carcinoma.
Ojala A; Nikkanen VN; Palojoki A; Paloheimo S
Ann Clin Res; 1977 Feb; 9(1):12-4. PubMed ID: 329741
[TBL] [Abstract][Full Text] [Related]
5. Bleomycin (NSC-125066) followed by cyclophosphamide (NSC-26271), vincristine (NSC-67574), methotrexate (NSC-740), and 5-fllorouracil (NSC-19893) for non-oat cell bronchogenic carcinoma.
Lanzotti VJ; Thomas DR; Holoye PY; Boyle LE; Smith TL; Samuels ML
Cancer Treat Rep; 1976 Jan; 60(1):61-8. PubMed ID: 63331
[TBL] [Abstract][Full Text] [Related]
6. Cyclophosphamide, doxorubicin, and cisplatin in the treatment of non-small cell bronchogenic carcinoma.
Evans WK; Feld R; DeBoer G; Osoba D; Curtis JE; Baker MA; Myers RE; Quirt IC; Pritchard KI; Brown TC; Kutas GJ; Blackstein ME; Ottema B; Millband L
Cancer Treat Rep; 1981; 65(11-12):947-54. PubMed ID: 7028256
[TBL] [Abstract][Full Text] [Related]
7. Cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP)--effective four-drug combination chemotherapy for metastatic non-oat cell bronchogenic carcinoma.
Bitran JD; Desser RK; DeMeester TR; Colman M; Evans R; Billings A; Griem M; Rubenstein L; Shapiro C; Golomb HM
Cancer Treat Rep; 1976 Sep; 60(9):1225-30. PubMed ID: 189920
[TBL] [Abstract][Full Text] [Related]
8. Intensive chemotherapy of small cell bronchogenic carcinoma.
Cohen MH; Creaven PJ; Fossieck BE; Broder LE; Selawry OS; Johnston AV; Williams CL; Minna JD
Cancer Treat Rep; 1977; 61(3):349-54. PubMed ID: 194691
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy for metastatic non-small cell bronchogenic carcinoma: EST 2575, generation III, HAM versus CAMP.
Ruckdeschel JC; Mehta CR; Salazar OM; Creech RH; Sponzo RW
Cancer Treat Rep; 1981; 65(11-12):959-63. PubMed ID: 6794909
[TBL] [Abstract][Full Text] [Related]
10. [Polychemotherapy of inoperable bronchogenic carcinoma: preliminary results (author's transl)].
Schulz V; Busch S; Endres P; Rubin R; Schönen M
Prax Klin Pneumol; 1979 Apr; 33 Suppl 1():660-1. PubMed ID: 88732
[TBL] [Abstract][Full Text] [Related]
11. Vindesine in the treatment of small cell anaplastic bronchogenic carcinoma.
Osterlind K; Dombernowsky P; Sørensen PG; Hansen HH
Cancer Treat Rep; 1981; 65(3-4):245-8. PubMed ID: 6263469
[TBL] [Abstract][Full Text] [Related]
12. [VP 16-213 in combination with endoxan, methotrexate and oncovin as polychemotherapy for bronchogenic carcinoma].
Ryssel HJ; Hasler E; Sonntag RW; Cavalli F; Martin J; Tschopp L; Brunner KW
Schweiz Med Wochenschr; 1977 Jul; 107(26):912-5. PubMed ID: 877537
[TBL] [Abstract][Full Text] [Related]
13. Chemo-immunotherapy for unresectable bronchogenic carcinoma.
Sarna GP; Lowitz BB; Haskell CM; Dorey FJ; Cline MJ
Cancer Treat Rep; 1978 May; 62(5):681-7. PubMed ID: 350397
[TBL] [Abstract][Full Text] [Related]
14. Methotrexate in the chemotherapy of lung cancer.
Smyth JF; Ford HT
Cancer Treat Rep; 1981; 65 Suppl 1():161-3. PubMed ID: 6275986
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapeutic studies in bronchogenic carcinoma by the Austrian study group.
Karrer K; Pridun N; Zwintz E
Cancer Chemother Rep 3; 1973 Mar; 4(2):207-13. PubMed ID: 4729324
[No Abstract] [Full Text] [Related]
16. [Prognostic factors in the chemotherapy of bronchial cancers].
Alberto P
Schweiz Med Wochenschr; 1974 Feb; 104(8):268-71. PubMed ID: 4360755
[No Abstract] [Full Text] [Related]
17. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
[TBL] [Abstract][Full Text] [Related]
18. Combination chemotherapy of advanced lung cancer: a randomized trial.
Hansen HH; Selawry OS; Simon R; Carr DT; van Wyk CE; Tucker RD; Sealy R
Cancer; 1976 Dec; 38(6):2201-7. PubMed ID: 187312
[TBL] [Abstract][Full Text] [Related]
19. Phase II randomized study of doxorubicin, vincristine, and 5-FU versus cyclophosphamide in advanced squamous cell carcinoma of the cervix.
Omura GA; Vélez-García E; Birch R
Cancer Treat Rep; 1981; 65(9-10):901-3. PubMed ID: 7196801
[TBL] [Abstract][Full Text] [Related]
20. [After care in bronchial carcinoma. Results of postoperative polychemotherapy].
Karrer K; Pridun N; Denck H
Fortschr Med; 1976 Mar; 94(7):379-85. PubMed ID: 184021
[No Abstract] [Full Text] [Related]
[Next] [New Search]
